Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO – Get Free Report) passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.24 and traded as low as $0.2345. Northwest Biotherapeutics shares last traded at $0.2633, with a volume of 6,559,719 shares changing hands.
Northwest Biotherapeutics Price Performance
The business has a 50-day moving average of $0.21 and a 200-day moving average of $0.24. The company has a market capitalization of $433.19 million, a P/E ratio of -0.01 and a beta of -0.74.
Northwest Biotherapeutics Company Profile
Northwest Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of personalized dendritic cell immunotherapies for the treatment of cancer. The company’s proprietary platform harnesses patient-derived dendritic cells to present tumor-specific antigens and stimulate a targeted immune response. By tailoring each vaccine to the individual patient’s tumor profile, the approach aims to improve outcomes and reduce off-target toxicity associated with conventional therapies.
The company’s lead candidate, DCVax®-L, is designed for patients with newly diagnosed or recurrent glioblastoma multiforme (GBM) and has advanced through a global Phase III clinical trial.
Recommended Stories
- Five stocks we like better than Northwest Biotherapeutics
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
Receive News & Ratings for Northwest Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Northwest Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
